ArriVent BioPharma
AVBP
99 hedge funds and large institutions have $732M invested in ArriVent BioPharma in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 9 closing their positions.
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
36% more capital invested
Capital invested by funds: $539M → $732M (+$193M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
19% more funds holding
Funds holding: 83 → 99 (+16)
12.01% more ownership
Funds ownership: 86.28% → 98.29% (+12%)
17% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Infinitum Asset Management
Fort Lauderdale,
Florida
|
+$28.1M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$22.3M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$14.5M |
| 4 |
F1I
Fund 1 Investments
Rincon,
Puerto Rico
|
+$11M |
| 5 |
CLG
Cooperman Leon G
|
+$8.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.26M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.4M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$2.35M |
| 4 |
Two Sigma Investments
New York
|
-$765K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$663K |
AVBP Hedge Fund Activity: Q2 2025 in Review
99 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2025, worth a combined $732M — up 36% from $539M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AVBP positions and 9 closed out — a net gain of 17 holders — while 25 added to existing stakes and 30 trimmed.
The largest buyer was Infinitum Asset Management, adding an estimated $28.1M. The largest seller was BlackRock, cutting an estimated $6.26M.
- 99 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2025, up from 83 in Q1 2025.
- Funds reported $732M of ArriVent BioPharma stock for Q2 2025, up 36% quarter-over-quarter.
- 26 funds opened new ArriVent BioPharma positions in Q2 2025 and 9 closed out, a net change of +17 holders.
- The largest ArriVent BioPharma buyer in Q2 2025 was Infinitum Asset Management, an estimated $28.1M added.
- The largest ArriVent BioPharma seller in Q2 2025 was BlackRock, an estimated $6.26M sold.
Based on aggregated 13F filings for Q2 2025.